Form 4: Relay Therapeutics Executive Sells Shares to Cover Tax Obligations After RSU Vesting

Relay Therapeutics' President of R&D, Donald A. Bergstrom, sold shares to cover tax obligations following the vesting of restricted stock units (RSUs).

Summary

• Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold a total of 79,450 shares of common stock across three transactions.
• These sales were executed to cover income tax withholding obligations related to the vesting of restricted stock units (RSUs).
• The sales occurred on January 28, 2025, January 29, 2025 and January 30, 2025 at prices of $4.63, $4.55 and $4.42 per share respectively.
• Bergstrom also acquired 176,400 shares through the vesting of RSUs on January 28, 2025.
• Following these transactions, Bergstrom beneficially owns 616,038 shares of Relay Therapeutics common stock, including 376,919 shares underlying RSUs.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Many biotech and pharmaceutical companies use RSUs as part of their executive compensation packages.
• It is standard practice for executives to sell a portion of their vested shares to cover income tax obligations.
• The number of shares sold and the timing of the sales are typical for RSU vesting events.

Stakeholder Impact

• The transactions have a minor impact on the overall shareholding structure of the company.
• The sales are not expected to significantly affect the company's operations or financial position.

Key Dates

Keywords

Relay Therapeutics, RLAY, insider trading, Form 4, stock sale, restricted stock units, RSU, executive compensation, Donald A. Bergstrom